ESMO Clinical Practice Guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia.

ESMO Clinical Practice Guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia.

3 июл. 2024 г. · The update covers the approval of time-limited ibrutinib–venetoclax in first line and new data on MRD-driven treatment.

3 июл. 2024 г. · ESMO Clinical Practice Guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia.

3 июл. 2024 г. · ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia

3 июл. 2024 г. · The update covers the approval of time-limited ibrutinib–venetoclax in first line and new data on MRD-driven treatment.

Supporting your clinical decisions with ESMO's regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts ... Guidelines by topic · ESMO Guidelines Committee · ESMO Guidelines Methodology

14 сент. 2024 г. · To provide more effective treatment option and clinical guidance, we perform a prospective, phase II trial with wider inclusion criteria and ...

7 дек. 2023 г. · The guidelines are in agreement that patients with early-stage CLL should not be treated with chemotherapy until they become symptomatic or display evidence of ...

EHA Working Group on CLL endorsed the ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up for CLL released on October 19, 2020.